News | May 18, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
The CDMO upgrade represents a transformational step for Remedium Lifecare
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Subscribe To Our Newsletter & Stay Updated
